RecruitingNCT05009797

PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation

PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation : LONGITUDINAL STUDY OF PATIENTS UNDERGOING RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION.


Sponsor

University Hospital, Lille

Enrollment

750 participants

Start Date

Feb 16, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patient undergoing atrial fibrillation catheter ablation
  • Able to give their consent

Exclusion Criteria4

  • Childs
  • Patient under guardianship
  • Patients unable to give their consent
  • Pregnancy

Interventions

PROCEDUREatrial fibrillation catheter ablation

The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.


Locations(1)

Institut Coeur-Poumon, CHU

Lille, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05009797


Related Trials